Cargando…

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

BACKGROUND: Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumour. However, rates of discordance vary considerabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Arlene, Morey, Adrienne, Brown, Belinda, Hastrich, Diana, Willsher, Peter, Ingram, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517741/ https://www.ncbi.nlm.nih.gov/pubmed/23176370 http://dx.doi.org/10.1186/1471-2407-12-555

Ejemplares similares

Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation
por: Ieni, Antonio, et al.
Publicado: (2014)

Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis
por: Ieni, Antonio, et al.
Publicado: (2014)

The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
por: Yang, Ziyan, et al.
Publicado: (2020)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
por: Lower, Elyse E, et al.
Publicado: (2017)

Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study
por: Jianna, Sun, et al.
Publicado: (2022)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
por: Kaufman, Peter A, et al.
Publicado: (2014)

An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Metastatic disease to the liver: Locoregional therapy strategies and outcomes
por: Zane, Kylie E, et al.
Publicado: (2021)

Lymph node metastases rate of locoregional and non-locoregional lymph node stations in gastric cancer
por: de Jong, Mees Hendrik Siert, et al.
Publicado: (2022)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases
por: Peng, Li, et al.
Publicado: (2021)

The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
por: Lee, Kyoungmin, et al.
Publicado: (2021)

Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
por: Palm, Christiane, et al.
Publicado: (2023)

Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer: A retrospective analysis of 107 cases
por: Peng, Li, et al.
Publicado: (2020)

Locoregional tumor burden and risk of mortality in metastatic breast cancer
por: Yang, Sherry X., et al.
Publicado: (2022)

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
por: Almstedt, Katrin, et al.
Publicado: (2023)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
por: Santini, Daniele, et al.
Publicado: (2017)

The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer
por: Yan, Yi, et al.
Publicado: (2016)

Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches
por: Ang, Celina, et al.
Publicado: (2016)

Locoregional therapy in de novo metastatic breast cancer. The unanswered question
por: Cardoso, Maria-Joao, et al.
Publicado: (2021)

The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor
por: Wang, Qi, et al.
Publicado: (2019)

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
por: Ye, Liu-Fang, et al.
Publicado: (2021)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
por: Kim, Hongsik, et al.
Publicado: (2019)

Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
por: DePalo, Danielle K., et al.
Publicado: (2023)

P16 and HPV discordance in metastatic carcinoma of cervical lymph nodes of unknown primary
por: Ralph, Alyssa, et al.
Publicado: (2015)

Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer
por: Chen, Peng-Yu, et al.
Publicado: (2013)

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
por: Moilanen, Tiina, et al.
Publicado: (2017)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR
por: Wise, Robert A., et al.
Publicado: (2017)

The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUV(max) on Predicting Survival in Patients with Rectal Cancer
por: Alçın, Göksel, et al.
Publicado: (2020)

Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapy
por: Steinauer, Kirsten, et al.
Publicado: (2014)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
por: Reinhorn, Daniel, et al.
Publicado: (2021)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
por: Serra, Francesco, et al.
Publicado: (2021)

Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017
por: Patterson, Tiffany, et al.
Publicado: (2022)

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis
por: Abudurexiti, Mierxiati, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8v6l53akqhd4ptql450dnbes2m